Tc-D-penicillamine-glucuronide: synthesis, radiolabeling, in vitro and in vivo evaluation

The current study was aimed at synthesizing a glucuronide derivative of D-penicillamine (D-PA) to be used for imaging purposes. First of all, D-PA-glucuronide (D-PA-Glu) was synthesized by experimental treatments starting with uridine 5'-diphospho-glucuronosyltransferase enzyme rich microsome p...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer biotherapy & radiopharmaceuticals 2011-10, Vol.26 (5), p.623
Hauptverfasser: Teksoz, Serap, Ichedef, Cigdem Acar, Ozyuncu, Seniha, Muftuler, Fazilet Zumrut Biber, Unak, Perihan, Medine, Ilker Emin, Ertay, Turkan, Eren, Mine Sencan
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 5
container_start_page 623
container_title Cancer biotherapy & radiopharmaceuticals
container_volume 26
creator Teksoz, Serap
Ichedef, Cigdem Acar
Ozyuncu, Seniha
Muftuler, Fazilet Zumrut Biber
Unak, Perihan
Medine, Ilker Emin
Ertay, Turkan
Eren, Mine Sencan
description The current study was aimed at synthesizing a glucuronide derivative of D-penicillamine (D-PA) to be used for imaging purposes. First of all, D-PA-glucuronide (D-PA-Glu) was synthesized by experimental treatments starting with uridine 5'-diphospho-glucuronosyltransferase enzyme rich microsome preparate. Then, the synthesized compound was labeled with technetium ([sup.99m]Tc) by using a reduction method with stannous chloride. Quality controls were performed by using high-performance liquid chromatography and thin-layer radio chromatography (TLRC). Radiolabeling yield of [sup.99m]Tc-D-PA-Glu was more than 98% according to TLRC results. In vitro evaluations of radiolabeled complexes were investigated on PC-3 human prostate cancer cells. [sup.99m]Tc-D-PA-Glu exhibited more accumulation on PC-3 cells versus [sup.99m]Tc-D-PA at 240 minutes. In order to determine its radiopharmaceutical potential, biodistribution studies were carried out in male Albino Wistar rats. The biodistribution results of [sup.99m]TcD-PA-Glu, showed the highest uptake in prostate at 120 minutes postinjection with the main excretion route being through kidneys and bladder. [sup.99m]Tc-D-PA-Glu and [sup.99m]Tc-D-PA have exhibited different biodistribution results. Key words: glucuronidation, PC-3 cell line, penicillamine, radiolabeling, scintigraphy, [sup.99m]Tc
doi_str_mv 10.1089/cbr.2010.0854
format Article
fullrecord <record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_infotracmisc_A270462798</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A270462798</galeid><sourcerecordid>A270462798</sourcerecordid><originalsourceid>FETCH-LOGICAL-g137t-9fb8d93b04bec575ee1c000d92c96e91c96d767be977a3bb465b223c8d42de183</originalsourceid><addsrcrecordid>eNptjs1LxDAQxXNQcF09ei943axJ-pHG27J-woKX9eBpyce0jqSJNG3B_97KevAgA294P94Mj5Arztac1erGmn4t2OxYXRYnZDHDgipZl2fkPKUPxljFKrkgb3tL7-gnBLTove4wAG39aMc-BnRwm6WvMLxDwrTKeu0wem3AY2hXGYZswqGPmQ7uaKaYwaT9qAeM4YKcNtonuPzdS_L6cL_fPtHdy-PzdrOjLc_lQFVjaqdywwoDtpQlALdzO6eEVRUoPquTlTSgpNS5MUVVGiFyW7tCOOB1viTXx7-t9nDA0MSh17bDZA8bIVlRCal-Uut_UvM46NDGAA3O_M_BN0ACYmo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Tc-D-penicillamine-glucuronide: synthesis, radiolabeling, in vitro and in vivo evaluation</title><source>Alma/SFX Local Collection</source><creator>Teksoz, Serap ; Ichedef, Cigdem Acar ; Ozyuncu, Seniha ; Muftuler, Fazilet Zumrut Biber ; Unak, Perihan ; Medine, Ilker Emin ; Ertay, Turkan ; Eren, Mine Sencan</creator><creatorcontrib>Teksoz, Serap ; Ichedef, Cigdem Acar ; Ozyuncu, Seniha ; Muftuler, Fazilet Zumrut Biber ; Unak, Perihan ; Medine, Ilker Emin ; Ertay, Turkan ; Eren, Mine Sencan</creatorcontrib><description>The current study was aimed at synthesizing a glucuronide derivative of D-penicillamine (D-PA) to be used for imaging purposes. First of all, D-PA-glucuronide (D-PA-Glu) was synthesized by experimental treatments starting with uridine 5'-diphospho-glucuronosyltransferase enzyme rich microsome preparate. Then, the synthesized compound was labeled with technetium ([sup.99m]Tc) by using a reduction method with stannous chloride. Quality controls were performed by using high-performance liquid chromatography and thin-layer radio chromatography (TLRC). Radiolabeling yield of [sup.99m]Tc-D-PA-Glu was more than 98% according to TLRC results. In vitro evaluations of radiolabeled complexes were investigated on PC-3 human prostate cancer cells. [sup.99m]Tc-D-PA-Glu exhibited more accumulation on PC-3 cells versus [sup.99m]Tc-D-PA at 240 minutes. In order to determine its radiopharmaceutical potential, biodistribution studies were carried out in male Albino Wistar rats. The biodistribution results of [sup.99m]TcD-PA-Glu, showed the highest uptake in prostate at 120 minutes postinjection with the main excretion route being through kidneys and bladder. [sup.99m]Tc-D-PA-Glu and [sup.99m]Tc-D-PA have exhibited different biodistribution results. Key words: glucuronidation, PC-3 cell line, penicillamine, radiolabeling, scintigraphy, [sup.99m]Tc</description><identifier>ISSN: 1084-9785</identifier><identifier>DOI: 10.1089/cbr.2010.0854</identifier><language>eng</language><publisher>Mary Ann Liebert, Inc</publisher><subject>Care and treatment ; Diagnosis ; Health aspects ; Liquid chromatography ; Penicillamine ; Prostate cancer</subject><ispartof>Cancer biotherapy &amp; radiopharmaceuticals, 2011-10, Vol.26 (5), p.623</ispartof><rights>COPYRIGHT 2011 Mary Ann Liebert, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Teksoz, Serap</creatorcontrib><creatorcontrib>Ichedef, Cigdem Acar</creatorcontrib><creatorcontrib>Ozyuncu, Seniha</creatorcontrib><creatorcontrib>Muftuler, Fazilet Zumrut Biber</creatorcontrib><creatorcontrib>Unak, Perihan</creatorcontrib><creatorcontrib>Medine, Ilker Emin</creatorcontrib><creatorcontrib>Ertay, Turkan</creatorcontrib><creatorcontrib>Eren, Mine Sencan</creatorcontrib><title>Tc-D-penicillamine-glucuronide: synthesis, radiolabeling, in vitro and in vivo evaluation</title><title>Cancer biotherapy &amp; radiopharmaceuticals</title><description>The current study was aimed at synthesizing a glucuronide derivative of D-penicillamine (D-PA) to be used for imaging purposes. First of all, D-PA-glucuronide (D-PA-Glu) was synthesized by experimental treatments starting with uridine 5'-diphospho-glucuronosyltransferase enzyme rich microsome preparate. Then, the synthesized compound was labeled with technetium ([sup.99m]Tc) by using a reduction method with stannous chloride. Quality controls were performed by using high-performance liquid chromatography and thin-layer radio chromatography (TLRC). Radiolabeling yield of [sup.99m]Tc-D-PA-Glu was more than 98% according to TLRC results. In vitro evaluations of radiolabeled complexes were investigated on PC-3 human prostate cancer cells. [sup.99m]Tc-D-PA-Glu exhibited more accumulation on PC-3 cells versus [sup.99m]Tc-D-PA at 240 minutes. In order to determine its radiopharmaceutical potential, biodistribution studies were carried out in male Albino Wistar rats. The biodistribution results of [sup.99m]TcD-PA-Glu, showed the highest uptake in prostate at 120 minutes postinjection with the main excretion route being through kidneys and bladder. [sup.99m]Tc-D-PA-Glu and [sup.99m]Tc-D-PA have exhibited different biodistribution results. Key words: glucuronidation, PC-3 cell line, penicillamine, radiolabeling, scintigraphy, [sup.99m]Tc</description><subject>Care and treatment</subject><subject>Diagnosis</subject><subject>Health aspects</subject><subject>Liquid chromatography</subject><subject>Penicillamine</subject><subject>Prostate cancer</subject><issn>1084-9785</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNptjs1LxDAQxXNQcF09ei943axJ-pHG27J-woKX9eBpyce0jqSJNG3B_97KevAgA294P94Mj5Arztac1erGmn4t2OxYXRYnZDHDgipZl2fkPKUPxljFKrkgb3tL7-gnBLTove4wAG39aMc-BnRwm6WvMLxDwrTKeu0wem3AY2hXGYZswqGPmQ7uaKaYwaT9qAeM4YKcNtonuPzdS_L6cL_fPtHdy-PzdrOjLc_lQFVjaqdywwoDtpQlALdzO6eEVRUoPquTlTSgpNS5MUVVGiFyW7tCOOB1viTXx7-t9nDA0MSh17bDZA8bIVlRCal-Uut_UvM46NDGAA3O_M_BN0ACYmo</recordid><startdate>20111001</startdate><enddate>20111001</enddate><creator>Teksoz, Serap</creator><creator>Ichedef, Cigdem Acar</creator><creator>Ozyuncu, Seniha</creator><creator>Muftuler, Fazilet Zumrut Biber</creator><creator>Unak, Perihan</creator><creator>Medine, Ilker Emin</creator><creator>Ertay, Turkan</creator><creator>Eren, Mine Sencan</creator><general>Mary Ann Liebert, Inc</general><scope/></search><sort><creationdate>20111001</creationdate><title>Tc-D-penicillamine-glucuronide: synthesis, radiolabeling, in vitro and in vivo evaluation</title><author>Teksoz, Serap ; Ichedef, Cigdem Acar ; Ozyuncu, Seniha ; Muftuler, Fazilet Zumrut Biber ; Unak, Perihan ; Medine, Ilker Emin ; Ertay, Turkan ; Eren, Mine Sencan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g137t-9fb8d93b04bec575ee1c000d92c96e91c96d767be977a3bb465b223c8d42de183</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Care and treatment</topic><topic>Diagnosis</topic><topic>Health aspects</topic><topic>Liquid chromatography</topic><topic>Penicillamine</topic><topic>Prostate cancer</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Teksoz, Serap</creatorcontrib><creatorcontrib>Ichedef, Cigdem Acar</creatorcontrib><creatorcontrib>Ozyuncu, Seniha</creatorcontrib><creatorcontrib>Muftuler, Fazilet Zumrut Biber</creatorcontrib><creatorcontrib>Unak, Perihan</creatorcontrib><creatorcontrib>Medine, Ilker Emin</creatorcontrib><creatorcontrib>Ertay, Turkan</creatorcontrib><creatorcontrib>Eren, Mine Sencan</creatorcontrib><jtitle>Cancer biotherapy &amp; radiopharmaceuticals</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Teksoz, Serap</au><au>Ichedef, Cigdem Acar</au><au>Ozyuncu, Seniha</au><au>Muftuler, Fazilet Zumrut Biber</au><au>Unak, Perihan</au><au>Medine, Ilker Emin</au><au>Ertay, Turkan</au><au>Eren, Mine Sencan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tc-D-penicillamine-glucuronide: synthesis, radiolabeling, in vitro and in vivo evaluation</atitle><jtitle>Cancer biotherapy &amp; radiopharmaceuticals</jtitle><date>2011-10-01</date><risdate>2011</risdate><volume>26</volume><issue>5</issue><spage>623</spage><pages>623-</pages><issn>1084-9785</issn><abstract>The current study was aimed at synthesizing a glucuronide derivative of D-penicillamine (D-PA) to be used for imaging purposes. First of all, D-PA-glucuronide (D-PA-Glu) was synthesized by experimental treatments starting with uridine 5'-diphospho-glucuronosyltransferase enzyme rich microsome preparate. Then, the synthesized compound was labeled with technetium ([sup.99m]Tc) by using a reduction method with stannous chloride. Quality controls were performed by using high-performance liquid chromatography and thin-layer radio chromatography (TLRC). Radiolabeling yield of [sup.99m]Tc-D-PA-Glu was more than 98% according to TLRC results. In vitro evaluations of radiolabeled complexes were investigated on PC-3 human prostate cancer cells. [sup.99m]Tc-D-PA-Glu exhibited more accumulation on PC-3 cells versus [sup.99m]Tc-D-PA at 240 minutes. In order to determine its radiopharmaceutical potential, biodistribution studies were carried out in male Albino Wistar rats. The biodistribution results of [sup.99m]TcD-PA-Glu, showed the highest uptake in prostate at 120 minutes postinjection with the main excretion route being through kidneys and bladder. [sup.99m]Tc-D-PA-Glu and [sup.99m]Tc-D-PA have exhibited different biodistribution results. Key words: glucuronidation, PC-3 cell line, penicillamine, radiolabeling, scintigraphy, [sup.99m]Tc</abstract><pub>Mary Ann Liebert, Inc</pub><doi>10.1089/cbr.2010.0854</doi></addata></record>
fulltext fulltext
identifier ISSN: 1084-9785
ispartof Cancer biotherapy & radiopharmaceuticals, 2011-10, Vol.26 (5), p.623
issn 1084-9785
language eng
recordid cdi_gale_infotracmisc_A270462798
source Alma/SFX Local Collection
subjects Care and treatment
Diagnosis
Health aspects
Liquid chromatography
Penicillamine
Prostate cancer
title Tc-D-penicillamine-glucuronide: synthesis, radiolabeling, in vitro and in vivo evaluation
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T16%3A56%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tc-D-penicillamine-glucuronide:%20synthesis,%20radiolabeling,%20in%20vitro%20and%20in%20vivo%20evaluation&rft.jtitle=Cancer%20biotherapy%20&%20radiopharmaceuticals&rft.au=Teksoz,%20Serap&rft.date=2011-10-01&rft.volume=26&rft.issue=5&rft.spage=623&rft.pages=623-&rft.issn=1084-9785&rft_id=info:doi/10.1089/cbr.2010.0854&rft_dat=%3Cgale%3EA270462798%3C/gale%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A270462798&rfr_iscdi=true